NAAA is ac ysteine hydrolase that catalyzes the biodegradation of PEA and OEA (Figure 1) , [1] twol ipids that suppress inflammation by activating the ligand-operated transcription factor,p eroxisome proliferator-activated receptor-a (PPAR-a). [2] Macrophages and other host defense cells constitutively generate PEA and OEA in amounts that are sufficient to fully engage PPAR-a. [3] This process is halted during inflammation, leading to ad ecrease in PPAR-a signaling and acceleration of the inflammatory response. [3] Accordingly,s mall-molecule NAAA inhibitors restore normal PEA and OEA levels in inflamed tissues and exert marked anti-inflammatory effects in animal models,pointing to NAAA as apotential target for therapy. [4] Figure 2i llustrates the three most potent classes of NAAA inhibitors described to date.E ach class is defined by the presence of ac hemical warhead (b-lactone, b-lactam, or isothiocyanate) that can react covalently with the catalytic cysteine of NAAA to form at hioester bond. [5] While potent and, in some cases,systemically active,these molecules share two features that limit their use as oral drugs:1)the presence of ar eactive warhead lowers their metabolic stability (for example, b-lactone 3) [6] or increases risk of allergic reactions (for example, b-lactam 4 and isothiocyanate 6); [7] and 2) the hydrophobic fragment that ensures target recognition by these agents negatively impacts drug-likeness.
Herein, we describe as eries of benzothiazole-piperazine derivatives that non-covalently inhibit NAAA ( Figure 2 ). Our experiments indicate that compound 8,arepresentative Figure 1 . NAAA hydrolyzes saturated and monounsaturated fatty acid ethanolamides (for example, PEA (1)) into fatty acid (for example, palmitic acid (2)) and ethanolamine. Figure 2 . Structures of published NAAA inhibitors (3, [6] 4,
[5b] 6 [8] ), activity-based NAAA probe (5) [9] (top), and compounds reported herein (bottom). member of this class,i sp otent, selective for NAAA, and orally available.Moreover, 8 crosses the blood-brain barrier, elevates PEA and OEA levels in the CNS,a nd is strongly active in am ouse model of MS.
As creening campaign to discover new scaffolds for NAAA inhibition yielded the low-potencyh it 7 (Table 1) .
To improve potency, we launched as tructure-activity relationship (SAR) study that started with the benzamide portion of 7.R emoval of the o-methyl group (9), or replacement of such ag roup with ah alogen (10, 11) , caused ac omplete loss of activity.B yc ontrast, substitutions with am ethoxy (12), methylsulfonyl (13), or ethylsulfonyl (14) group yielded compounds of progressively greater potency. Since moving the ethylsulfonyl substituent to the meta-o r para-position of the phenyl ring strongly reduced activity (15, 16) , we focused our exploration on o-sulfonyl derivatives containing linear, branched, or cyclic alkyl groups ( Table 2) . We found that potencywas highly sensitive to length and size of the alkyl fragment, with bulkier substituents producing weaker inhibition (for example, 18 and 23).
Subsequently,w et urned to the benzothiazole system, using 14 as an entry point ( Table 3) . Removal of the 6-F substituent did not affect potency( 24), whereas insertion of electron-withdrawing (25, 26)or-donating (27, 28)groups was detrimental. Moving ahalogen to various positions of the ring caused either minor effects or adecrease in potency(29-32).
Therole of the piperazine was probed by replacing it with alternatively oriented piperidines ( Table 4) . Thec ompounds obtained were either weakly (33)o rm oderately (34)a ctive, with 33 being approximately 60 times less potent than 14.Loss of potency was also observed with 35,i nw hich am ethylene bridge replaces the benzamide carbonyl of 14.T oexamine the effect of conformational changes in the piperazine ring,w e introduced one or two methyl groups at various positions of this moiety (36-39). These attempts did not lead to improvements in potency, but confirmed the role of am onosubstituted piperazine in this region, as shown by the drop in activity caused by 2,2-dimethyl substitution (38). Supporting this,w en oted that potency was highly sensitive to the configuration of the methyl group,w ith 40 (the (R)-enantiomer of 36)being 15 times less potent than the (S)-enantiomer 8.A lkyl chain modifications on the sulfonyl substituent of 8 yielded no further improvement (41 and 42).
We focused subsequent mechanistic work on 8 because of its greater water solubility,compared to other similarly potent compounds (Table 5 ; Supporting Information, Table S1 ). To support this work, an easily scalable synthesis was developed (Scheme 1).
Current NAAA inhibitors react covalently with the catalytic cysteine of NAAA. [5] We used four approaches to probe the interaction of 8 with NAAA. First, we incubated purified human (h)N AAA (2 mm)with 8 (50 mm), digested it with trypsin, and searched for covalent adducts using liquid chromatography mass spectrometry (LC-MS). As ap ositive control, we included the b-lactam 4 (20 mm), for which ac ovalent interaction with NAAA is documented.
[5b]
Incubating hNAAA with 4 yielded the expected acylated peptide,w hereas no such adduct was found when hNAAA was exposed to either 8 or vehicle ( Figure 3A) . Similarly,no covalent adducts were retrieved by as earch through the entire peptide map of hNAAA (Supporting Information, Figure S1 ). Second, we incubated hNAAA (4.0 mm)with 4 or 8 (1.0 mm), precipitated the protein, and measured compounds in the supernatant by LC-MS.W hereas 4 was Figure 3B ). Third, we investigated whether 8 prevents the binding of the covalent activity-based probe 5 to NAAA. [9] As previously shown, [9] 5 labeled hNAAA in cell extracts,a nd this effect was blocked by incubation with 4 ( Figure 3C ). In contrast, incubation with 8 only partially antagonized hNAAA labeling by 5 and at short incubation times ( Figure 3C ). Lastly,k inetic analyses revealed that 8 inhibits NAAA by an uncompetitive mechanism ( Figure 4A ,B). Theresults identify 8 as the first non-covalent NAAA inhibitor disclosed to date. Theu nprecedented mechanistic profile of 8 prompted us to test the compounds usefulness as an oral agent. In vitro studies demonstrated that 8 is soluble in aqueous buffer (pH 7.4) and stable in mouse plasma (Table 5) . Similarly, 8 is stable in mouse liver microsomes (MLM).
Experiments in mice showed that 8 is extensively absorbed after oral administration ( Figure 5A ). Thepharmacokinetic (PK) parameters listed in Table 5indicate that 8 had excellent oral bioavailability.I mportantly, 8 crossed the blood-brain barrier,r eaching ab rain-to-plasma ratio of 0.2 and causing as ubstantial accumulation of PEA and OEA in brain tissue ( Figure 5A,B) . No changes were seen in the levels of the anandamide,a ne ndocannabinoid lipid amide that is degraded by fatty acid amide hydrolase (FAAH) rather than by NAAA. [3] Aselectivity screen showed that 8 (10 mm)had little or no effect on apanel of more than 50 receptors,ion channels,and transporters (Supporting Information, Table S2 ). Moreover, as expected from our target engagement studies ( Figure 5B ), 8 had only aw eak inhibitory effect on FAAH (IC 50 % 10 mm), [10] and no effect on either acid ceramidase (a cysteine amidase that has 33-34 %identity with NAAA) [1] or monoacylglycerol lipase (a serine hydrolase that degrades the endocannabinoid 2-arachidonoyl-sn-glycerol). [11] MS is an euroinflammatory disorder accompanied by alterations in cerebrospinal and plasma levels of PEA and OEA.
[12] PEA administration attenuates spasticity in the experimental allergic encephalomyelitis (EAE) model of MS. [13] Consequently,wetested whether accrual of PEA/OEA by treatment with 8 might be beneficial in this model. EAE mice and sham-immunized controls were treated with 8 (30 mg kg À1 ,twice daily) or vehicle for 28 days,while recording clinical scores and body weight gain. Clinical scores were generated using as ymptom scale that ranged from 0( no clinical signs) to 5( moribund). [14] Figure 6shows that treatment with 8 did not affect shamimmunized mice,whereas it delayed disease onset, attenuated symptom intensity,a nd normalized body weight in EAE animals.M oreover, 8 reduced mononuclear cell infiltration and microglia activation-two anatomical correlates of disease-in the spinal cord of EAE mice (Supporting Information, Figure S2 ). Further underscoring the superiority of 8 relative to known NAAA inhibitors,t he highly potent covalent b-lactam derivative 4 had no effect in the EAE model (Supporting Information, Figure S3 ).
In summary,t he present study describes an ovel class of benzothiazole-piperazine derivatives that inhibit NAAA by an on-covalent, uncompetitive mechanism. Ar epresentative member of this class, 8,s hows excellent oral PK properties and good brain penetration. Thestrong protective activity of 8 in am ouse model of MS is similar to those of other agents used to target this disease. [15] Compound 8 exemplifies anew generation of non-covalent NAAA inhibitors that may find therapeutic applications in the treatment of neuroinflammation. 
